Primary and metastatic breast tumors cross-talk to influence immunotherapy responses

References

• Weigelt B, Peterse JL, Van ‘T Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591–10. doi:10.1038/nrc1670.
   PubMed Web of Science ®Google Scholar
• Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989;8:98–101.
   PubMed Web of Science ®Google Scholar
• Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862–870. doi:10.1016/j.ijrobp.2003.09.012.
   PubMed Web of Science ®Google Scholar
• Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Engleman EG, Prestwood TR, Chabon J, Bendall SC. Systemic immunity is required for effective cancer immunotherapy. Cell. 2017;168:487–502 e415. doi:10.1016/j.cell.2016.12.022.
   PubMed Web of Science ®Google Scholar
• Oliver AJ, Darcy PK, Trapani JA, Kershaw MH, Slaney CY. Cross-talk between tumors at anatomically distinct sites. The FEBS Journal. 2020. doi:10.1111/febs.15316.
   Web of Science ®Google Scholar
• Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol. 1999;162:5728–5737.
   PubMed Web of Science ®Google Scholar
• Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19:108–119. doi:10.1038/s41590-017-0022-x.
   PubMed Web of Science ®Google Scholar
• Tung KH, Ernstoff MS, Allen C, Shu S. A review of exosomes and their role in the tumor microenvironment and host-tumor “Macroenvironment”. J Immunol Sci. 2019;3:4–8. doi:10.29245/2578-3009/2019/1.1165.
   PubMedGoogle Scholar
• Zuckerman NS, Yu H, Simons DL, Bhattacharya N, Carcamo-Cavazos V, Yan N, Dirbas FM, Johnson DL, Schwartz EJ, Lee PP. Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients. Int J Cancer. 2013;132(11):2537–2547. doi:10.1002/ijc.27933.
   PubMed Web of Science ®Google Scholar
• Walker R, Poleszczuk J, Pilon-Thomas S, Kim S, Anderson A, Czerniecki BJ, … Enderling H. Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy. Sci Rep. 2018;8:9474. doi:10.1038/s41598-018-27718-1.
   PubMed Web of Science ®Google Scholar
• Devaud C, John LB, Westwood JA, Yong CS, Beavis PA, Schwendener RA, … Kershaw MH. Cross-talk between tumors can affect responses to therapy. Oncoimmunology. 2015;4:e975572. doi:10.4161/2162402X.2014.975572.
   PubMed Web of Science ®Google Scholar
• Taggart D, Andreou T, Scott KJ, Williams J, Rippaus N, Brownlie RJ, … Lorger M. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking. Proc Natl Acad Sci U S A. 2018;115:E1540–E1549. doi:10.1073/pnas.1714089115.
   PubMed Web of Science ®Google Scholar
• Oliver AJ, Lau PKH, Unsworth AS, Loi S, Darcy PK, Kershaw MH, Slaney CY. Tissue-dependent tumor microenvironments and their impact on immunotherapy responses. Front Immunol. 2018;9:70. doi:10.3389/fimmu.2018.00070.
   PubMed Web of Science ®Google Scholar
• Horton BL, Fessenden TB, Spranger S. Tissue site and the cancer immunity cycle. Trends Cancer. 2019;5:593–603. doi:10.1016/j.trecan.2019.07.006.
   PubMed Web of Science ®Google Scholar
• Pao W, Ooi CH, Birzele F, Ruefli-Brasse A, Cannarile MA, Reis B, Reed JC, Schubert DA, Hatje K, Pelletier N. Tissue-specific immunoregulation: a call for better understanding of the “immunostat” in the context of cancer. Cancer Discov. 2018;8:395–402. doi:10.1158/2159-8290.CD-17-1320.
   PubMed Web of Science ®Google Scholar
• Oliver AJ, Darcy PK, Kershaw MH, Slaney CY. Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses. Journal of Thoracic Disease. 2020. doi:10.21037/jtd.2020.03.64.
   PubMed Web of Science ®Google Scholar
• Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228–241. doi:10.1038/nrclinonc.2015.215.
   PubMed Web of Science ®Google Scholar
• Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Marincola FM, Zhou X, Bedognetti D, Hendrickx W. Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness. Cancer Immunol Res. 2016;4:600–610. doi:10.1158/2326-6066.CIR-15-0149.
   PubMed Web of Science ®Google Scholar
• Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Loi S, Byrne DJ, Teo ZL, Dushyanthen S. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24:986–993. doi:10.1038/s41591-018-0078-7.
   PubMed Web of Science ®Google Scholar
• Oliver AJ, Davey AS, Keam SP, Mardiana S, Chan JD, von Scheidt B, … Slaney CY. Tissue-specific tumor microenvironments influence responses to immunotherapies. Clin Transl Immunology. 2019;8:e1094. doi:10.1002/cti2.1094.
   PubMed Web of Science ®Google Scholar
• Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, … Cox J. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13:731–740. doi:10.1038/nmeth.3901.
   PubMed Web of Science ®Google Scholar
• Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Anderson RL, Sloan EK, Moseley JM, Anderson RL. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res. 2005;3:1–13.
   PubMed Web of Science ®Google Scholar
• Li R, Huang Y, Lin J. Distinct effects of general anesthetics on lung metastasis mediated by IL-6/JAK/STAT3 pathway in mouse models. Nat Commun. 2020;11(1):642. doi:10.1038/s41467-019-14065-6.
   PubMed Web of Science ®Google Scholar
• Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, Kershaw MH, Pegram HJ, Stacker SA, Achen MG. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol Ther. 2014;22:18–27. doi:10.1038/mt.2013.219.
   PubMed Web of Science ®Google Scholar
• Kim IS, Gao Y, Welte T, Wang H, Liu J, Janghorban M, Zhang XH, Niu Y, Goldstein A, Zhao N. Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nat Cell Biol. 2019;21:1113–1126. doi:10.1038/s41556-019-0373-7.
   PubMed Web of Science ®Google Scholar
• Scrimieri F, Askew D, Corn DJ, Eid S, Bobanga ID, Bjelac JA, Huang AY, Allen F, Othman YS, Wang SCG. Murine leukemia virus envelope gp70 is a shared biomarker for the high-sensitivity quantification of murine tumor burden. Oncoimmunology. 2013;2:e26889. doi:10.4161/onci.26889.
   PubMed Web of Science ®Google Scholar
• Ouzounova M, Lee E, Piranlioglu R, El Andaloussi A, Kolhe R, Demirci MF, Korkaya H, Asm I, Chadli A, Hassan KA. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. Nat Commun. 2017;8:14979. doi:10.1038/ncomms14979.
   PubMed Web of Science ®Google Scholar
• Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer. 1982;30(1):107–112. doi:10.1002/ijc.2910300118.
   PubMed Web of Science ®Google Scholar
• Guerin MV, Regnier F, Feuillet V, Vimeux L, Weiss JM, Bismuth G, Bercovici N, Guilbert T, Thoreau M, Finisguerra V. TGFbeta blocks IFNalpha/beta release and tumor rejection in spontaneous mammary tumors. Nat Commun. 2019;10:4131. doi:10.1038/s41467-019-11998-w.
   PubMed Web of Science ®Google Scholar
• Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, Parker BS, Zanker D, Chan C-L, Cumming HE. Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. NPJ Precis Oncol. 2019;3:21. doi:10.1038/s41698-019-0093-2.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405–414. doi:10.1038/nri3845.
   PubMed Web of Science ®Google Scholar
• Lu C, Klement JD, Ibrahim ML, Xiao W, Redd PS, Nayak-Kapoor A, … Liu K. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. J Immunother Cancer. 2019;7:157. doi:10.1186/s40425-019-0635-8.
   PubMed Web of Science ®Google Scholar
• Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Fuchs SY, Beiting DP, Girondo MA, Peck AR. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell. 2017;31:194–207. doi:10.1016/j.ccell.2017.01.004.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kroemer G. Calreticulin and type I interferon: an unsuspected connection. Oncoimmunology. 2017;6(3):e1288334. doi:10.1080/2162402X.2017.1288334.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Sistigu A, Yamazaki T, Vitale I, Zitvogel L, Kroemer G. Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. Oncoimmunology. 2015;4:e988042. doi:10.4161/2162402X.2014.988042.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Petroni G, Kroemer G. Immunogenicity of cell death driven by immune effectors. J Immunother Cancer. 2020;8(1):e000802. doi:10.1136/jitc-2020-000802.
   PubMed Web of Science ®Google Scholar
• Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, McWhirter SM, Vu UT, Francica BJ, Banda T. Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity. Cell Rep. 2018;25:3074–3085 e3075. doi:10.1016/j.celrep.2018.11.047.
   PubMed Web of Science ®Google Scholar
• Liu J, Blake SJ, Yong MC, Harjunpaa H, Ngiow SF, Takeda K, Teng MW, O’Donnell JS, Allen S, Smyth MJ. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6:1382–1399. doi:10.1158/2159-8290.CD-16-0577.
   PubMed Web of Science ®Google Scholar
• Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Parker BS, Caramia F, Loi S, Darcy PK. Neoadjuvant interferons: critical for effective PD-1-based immunotherapy in TNBC. Cancer Immunol Res. 2017;5:871–884. doi:10.1158/2326-6066.CIR-17-0150.
   PubMed Web of Science ®Google Scholar
• Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Wargo JA, Lewis C, Hwu W-J, Hanna E. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24:1649–1654. doi:10.1038/s41591-018-0197-1.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Prins RM, Ellingson BM, Rytlewski JA, Sanders CM. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25:477–486. doi:10.1038/s41591-018-0337-7.
   PubMed Web of Science ®Google Scholar
• Pelster MS, Amaria RN. Neoadjuvant immunotherapy for locally advanced melanoma. Curr Treat Options Oncol. 2020;21(2):10. doi:10.1007/s11864-020-0700-z.
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Pardoll DM, Yang SC, Jones DR, Broderick S. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976–1986. doi:10.1056/NEJMoa1716078.
   PubMed Web of Science ®Google Scholar